Elicio Therapeutics, Inc.
Company Stats
- Market Cap
- $47.8M
- as of Sep 30, 2026
- Shares Outstanding
- 26.3M
- Free Float
- 51.9%
Income Statement
- Operating Income
- -$37.7M
- Net Income
- -$39.6M
- EBITDA
- -$37.5M
Cash Flow
- Free Cash Flow
- -$37.0M
- FCF Yield
- -77.3%
- Owner FCF Yield
- -82.9%
Balance Sheet
- Cash & Equivalents
- $18.6M
Returns & Capital
- SBC, 3Y Avg
- $1.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$37.0M | — |
| FY2024 | — | -$37.2M | — |
| FY2023 | — | -$32.8M | — |
| FY2022 | $2.3M | -$22.8M | -992.3% |
| FY2021 | $28.3M | -$53.0M | -187.3% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges